Dmitry Zaletaev

Prof. Dmitry Zaletaev

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1992 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TJTim Jordan
Tim Jordan
IHIsabel Hanson
Isabel Hanson
DZDmitry Zaletaev
Dmitry Zaletaev
SHShirley Hodgson
Shirley Hodgson
JPJane Prosser
Jane Prosser
VHVeronica van Heyningen
Veronica van Heyningen

14 June 2019 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
MNMarina V. Nemtsova
Marina V. Nemtsova
DZDmitry Zaletaev
Dmitry Zaletaev
IBIrina V. Bure
Irina V. Bure
DMDmitry S. Mikhaylenko
Dmitry S. Mikhaylenko
EKEkaterina B. Kuznetsova
Ekaterina B. Kuznetsova
Andrey A. Zamyatnin Jr.Andrey A. Zamyatnin Jr.
Andrey A. Zamyatnin Jr.
Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects about 1% of the world’s population. The etiology of RA remains unknown. It is considered to occur in the presence of genetic and environmental factors. An increasing body of evidence pinpoints that epigenetic modifications play an important role in the regulation of RA pathogenesis. Epigenetics causes heritable phenotype changes that are not determined by changes in the DNA sequence. The major epigenetic mechanisms include DNA methylation, histone proteins modifications and changes in gene expression caused by microRNAs and other non-coding RNAs. These modifications are reversible and could be modulated by diet, drugs, and other environmental factors. Specific changes in DNA methylation, histone modifications and abnormal expression of non-coding RNAs associated with RA have already been identified. This review focuses on the role of these multiple epigenetic factors in the pathogenesis and progression of the disease, not only in synovial fibroblasts, immune cells, but also in the peripheral blood of patients with RA, which clearly shows their high diagnostic potential and promising targets for therapy in the future.

1 July 1993 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
IMIsabel M.HAnson
Isabel M.HAnson
ASAnne Seawright
Anne Seawright
KHKaren Hardman
Karen Hardman
SHShirley Hodgson
Shirley Hodgson
DZDmitry Zaletaev
Dmitry Zaletaev
VHVeronica van Heyningen
Veronica van Heyningen
Aniridia is a congenital malformation of the eye, chiefly characterised by Iris hypoplasla, which can cause blindness. The PAX6 gene was Isolated as a candidate aniridia gene by positional cloning from the smallest region of overlap of aniridia-associated deletions. Subsequently PAX6 Intragenic mutations were demonstrated In Smalleye, a mouse mutant which is an animal model for anirldia, and six human anlridia patients. In this paper we describe four additional PAX6 point mutations in anlridia patients, both sporadic and farnillal. These mutations highlight regions of the gene which are essential for normal PAX6 function. In addition, the frequency at which we have found PAX6 mutations suggests that lesions in PAX6 will account for most cases of anlridia.

Verified
Journal Article
Open access
PDF file
IBIrina Bure
Irina Bure
MNMarina V. Nemtsova
Marina V. Nemtsova
DZDmitry Zaletaev
Dmitry Zaletaev
The epithelial–mesenchymal transition (EMT) is thought to be at the root of invasive and metastatic cancer cell spreading. E-cadherin is an important player in this process, which forms the structures that establish and maintain cell–cell interactions. A partial or complete loss of E-cadherin expression in the EMT is presumably mediated by mechanisms that block the expression of E-cadherin regulators and involve the E-cadherin-associated transcription factors. The protein is involved in several oncogenic signaling pathways, such as the Wnt/β-catenin, Rho GTPase, and EGF/EGFR, whereby it plays a role in many tumors, including gastric cancer. Such noncoding transcripts as microRNAs and long noncoding RNAs—critical components of epigenetic control of gene expression in carcinogenesis—contribute to regulation of the E-cadherin function by acting directly or through numerous factors controlling transcription of its gene, and thus affecting not only cancer cell proliferation and metastasis, but also the EMT. This review focuses on the role of E-cadherin and the non-coding RNAs-mediated mechanisms of its expressional control in the EMT during stomach carcinogenesis.

1 May 2016 in Cancer Letters
Verified
Journal Article
Closed access
TKTatiana Kekeeva
Tatiana Kekeeva
ATAlexander Sergeevich Tanas
Alexander Sergeevich Tanas
AKA. Kanygina
A. Kanygina
DAD. Alexeev
D. Alexeev
ASA. Shikeeva
A. Shikeeva
DZDmitry Zaletaev
Dmitry Zaletaev

16 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MNMarina V. Nemtsova
Marina V. Nemtsova
AKAlexey Kalinkin
Alexey Kalinkin
EKEkaterina B. Kuznetsova
Ekaterina B. Kuznetsova
IBIrina V. Bure
Irina V. Bure
EAEkaterina A. Alekseeva
Ekaterina A. Alekseeva
VSVladimir Strelnikov
Vladimir Strelnikov
Somatic mutation profiling in gastric cancer (GC) enables main driver mutations to be identified and their clinical and prognostic value to be evaluated. We investigated 77 tumour samples of GC by next-generation sequencing (NGS) with the Ion AmpliSeq Hotspot Panel v2 and a custom panel covering six hereditary gastric cancer predisposition genes (BMPR1A, SMAD4, CDH1, TP53, STK11 and PTEN). Overall, 47 somatic mutations in 14 genes were detected; 22 of these mutations were novel. Mutations were detected most frequently in the CDH1 (13/47) and TP53 (12/47) genes. As expected, somatic CDH1 mutations were positively correlated with distant metastases (p = 0.019) and tumours with signet ring cells (p = 0.043). These findings confirm the association of the CDH1 mutations with diffuse GC type. TP53 mutations were found to be significantly associated with a decrease in overall survival in patients with Lauren diffuse-type tumours (p = 0.0085), T3-T4 tumours (p = 0.037), and stage III-IV tumours (p = 0.013). Our results confirm that the detection of mutations in the main driver genes may have a significant prognostic value for GC patients and provide an independent GC-related set of clinical and molecular genetic data.